Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Molecular Templates finds new investor in $8.5mm Series C; round extended by $3.5mm

Executive Summary

Molecular Templates Inc. (developing next-generation antibody-drug conjugates for cancer) raised $8.5mm through its Series C round. New investor Excel Venture Management led (and takes two seats on the board), and was joined by returning backer Santé Ventures. The company also announced receipt of a $10.6mm grant from the Cancer Prevention & Research Institute of Texas last year. Funds will go towards upcoming Phase I trials of lead compound MT3724, an engineered toxin body for B-cell lymphomas.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies